Pi is 2210261215001376
-
Upload
hussein-faour -
Category
Documents
-
view
215 -
download
0
description
Transcript of Pi is 2210261215001376
-
CASE REPORT OPEN ACCESSInternational Journal of Surgery Case Reports 10 (2015) 3540
Contents lists available at ScienceDirect
International Journal of Surgery Case Reports
journa l h omepage: www.caserepor ts .com
Aggressive multimodal therapy may prolong diserecurrent primary retroperitoneal embryonal car
Martin Strakaa,, Viktor Manasekb, Miroslav Stursac, Romana a Department of Surgery, Comprehensive Cancer Centre and AGEL Research and Training Institute, Novy JicinJicin Czech Republicb Department of Oncology and Radiotherapy, Comprehensive Cancer Centre and AGEL Research and Trainingc Department of Urology, Comprehensive Cancer Centre and AGEL Research and Training Institute, Novy Jicind Department o ovy Ji
a r t i c l
Article history:Received 28 JaAccepted 9 MaAvailable onlin
Keywords:Germ cell tumExtragonadalRelapseRecurrenceSurgeryAdjuvant therapy
eal ex
t a caser theresiduvant
yeargland, which was treated with surgery and 4 cycles of salvage VeIP chemotherapy. Seven months afterthe second surgical intervention the patient underwent multivisceral desperation surgery for earlymetastatic disease progression followed by 2 cycles of salvage TIP chemotherapy. The patient is currentlydisease-free at 34 months.CONCLUSION: Initial postchemotherapy retroperitoneal lymph node dissection is crucial for local
1. Introdu
Gonadaloriginate frmalignant cells in themetastatic have their regressed (a
Currentlonadal orig
Abbreviatiotumour; IGCCCtidisciplinary and cisplatin; VeIP chemothchemotherapypean Organisatomographyc
CorresponE-mail add
http://dx.doi.o2210-2612/ license (http:/retroperitoneal disease control. Aggressively treated metastatic recurrent disease does not precludeprolonged survival. Despite a generally poor prognosis, repeated complex oncosurgical therapy forretroperitoneal extragonadal tumours may be worthwhile.
2015 Z. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access articleunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ction
(GGCTs) and extragonadal germ cell tumours (EGGCTs)om primordial germ cells. EGGCTs may develop bytransformation of residual, misplaced primitive germ
sagittal midline, or may be a group of misdiagnosedGGCTs [1]. Metastatic retroperitoneal tumours mayprimary small and unrecognised, or spontaneouslyutoinfarcted, burnt-out) [24].y, 5% of malignant GGCTs are thought to be of extrag-in [5]. Patients with EGGCTs are classied into good,
ns: GGCT, gonadal germ cell tumour; EGGCT, extragonadal germ cellG, International Germ Cell Cancer Collaborative Group; MDT, mul-
team; BEP chemotherapy, chemotherapy with bleomycin, etoposidG-CSF prophylaxis, granulocyte-colony stimulating factor profylaxis;erapy, chemotherapy with vinblastine, ifosfamide and cisplatin; TIP, chemotherapy with paclitaxel, ifosfamid and cisplatin; EORTC, Euro-tion for Research and Treatment of Cancer; PET/CT, positron emissionomputed tomography; RPLND, retroperitoneal lymphadenectomy.ding author. Tel.: +420 732 224 226.ress: [email protected] (M. Straka).
intermediate and poor prognosis categories based on primarytumour site, serum tumour marker levels and metastatic spread[6,7]. While GGCTs are typically curable with a high ve-yearsurvival rate (more than 90% when diagnosed at early stage)[8], nonseminomatous, retroperitoneal EGGCTs present with poorprognostic features in 50%, have frequent metastases in 76% and ave-year survival rate of 62%. Based on therapy response rate (68%)and a relapse rate of 50%, retroperitoneal EGGCTs are presumed tobelong to a poor prognosis group even if they full the IGCCCG crite-ria for good, or intermediate prognosis [5]. Embryonal carcinoma isan undifferentiated, pluripotent germinal cell neoplasm. This rareand complex malignancy should be managed by an experiencedmultidisciplinary team (MDT) in specialised centres [9].
2. Presentation of the case
A 42-year-old, obese (BMI 34.4 kg m2), Caucasian male pre-sented with left sided obstructive nephropathy due to a retroperi-toneal primary in 10/2007. Retroperitoneal lymphadenopathy onabdominal ultrasonography (USG) and computed tomography(CT) raised suspicion of lymphoma (Fig. 1). After ureteral stentplacement laparoscopic biopsy was performed. The histopathology
rg/10.1016/j.ijscr.2015.03.0182015 Z. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND/creativecommons.org/licenses/by-nc-nd/4.0/).f Pathology, Comprehensive Cancer Centre and AGEL Research and Training Institute, N
e i n f o
nuary 2015rch 2015e 12 March 2015
our
a b s t r a c t
INTRODUCTION: Primary retroperitona poor prognosis.PRESENTATION OF THE CASE: We reporwith negative open testes biopsy. Aftwith extirpation of a retroperitoneal to be a mature teratoma, and no adjuThe patient had regular follow-up. 3.5ase-free survival incinoma
Andelovad
Hospital, Purkynova 2138-16, 741 01 Novy
Institute, Novy Jicin Hospital, Czech Republic Hospital, Czech Republiccin Hospital, Czech Republic
tragonadal tumours relapsing after initial chemotherapy have
e of primary retroperitoneal embryonal carcinoma in a patient rst line of chemotherapy (4 cycles BEP) secondary surgeryal mass was performed. The residuum proved histologically
treatment was given according to current recommendations.s later, patient developed recurrence in the ipsilateral adrenal
-
CASE REPORT OPEN ACCESS36 M. Straka et al. / International Journal of Surgery Case Reports 10 (2015) 3540
Fig. 1. (A) MeCalcication in
revealed a gcarcinoma cells (1%) (FCD30, PLAPnegative. Balevel, the diInternationria. The casefor consens
The patapy (bleom15, cispla2007Februand septic SubsequentstimulatingAmgen Eurcomplete exphadenectoteratoma w(Fig. 4). Thalmost 3.5 ying the patof HCG (5sion, the papancreatectresect the tastatatic lesion of the right adrenal gland. (B) Interaortocaval and peripancreatic lym metastatic lesion below right renal vascular pedicle.
erminal tumour formed predominantly by embryonalcells (99%) and a small proportion of choriocarcinomaig. 2). Immunohistochemistry staining was positive for
and HCG (Fig. 3). Bilateral open testes biopsy provedsed on the CT, MRI, histopathology and tumour markersease was staged as intermediate risk according to theal Germ Cell Cancer Collaborative Group (IGCCCG) crite-
was presented at a multidisciplinary team conferenceus decision-making on multimodal treatment.ient was given a course of 1st-line BEP chemother-ycin 30 IU day 1, 8, and 15, etoposid 100 mg/qm daytin 20 mg/qm day 15) (4 cycles q3w) (Novemberary 2008). After the rst cycle, febrile neutropeniashock occurred, but this was managed successfully.
chemotherapy was delivered with granulocyte-colony factor (G-CSF) prophylaxispeglgrastim (Neulasta,ope B.V.(NLD)) and was uneventful. In April 2008,tirpation of tumour residuum and retroperitoneal lym-my (RPLND) was performed and structures of matureere revealed on nal histopathological examination
e patient experienced complete clinical remission forears. Disease progression occurred in May 2011 involv-ients left adrenal as a solitary lesion. Increased level.7 IU/l) was recorded and based on the MDT deci-tient underwent surgery. Left adrenalectomy, partialomy and splenectomy were performed in order toadrenal lesion in close relation to the pancreatic tail
pseudocystMetastatic than 10 mhistopatholof 2nd-line
Fig. 2. Retrop(100).phadenopathy. (C) Bilateral metastatic retroperitoneal disease. (D)
(a complication after the rst surgical intervention).embryonal carcinoma with high mitotic activity (moreitoses per 10 high-power elds) was conrmed onogy. After the surgery, the patient received a full 4 cycles
VeIP chemotherapy q3w (vinblastin 0.11 mg/kg day
eritoneal lymphonode inltrated by embryonal carcinoma, HE stain
-
CASE REPORT OPEN ACCESSM. Straka et al. / International Journal of Surgery Case Reports 10 (2015) 3540 37
Fig. 3. ImmunPositivity for C
12, ifosfamplus G-CSFOrganisatiotion (Augusnosed early(Fig. 5). Thtomographohistochemistry staining. (A) High proliferation activity Ki 67 stain (200). (B) PositivK AE 1/3 (400).
Fig. 4. Mature teratoma, HE stain (100).
ide 1.2 g/qm day 15, cisplatin 20 mg/qm day 15) prophylaxis according to current EORTC (Europeann for Research and Treatment of Cancer) recommenda-tOctober 2011). Second disease progression was diag-
after systemic therapy completion in February 2012e PET/CT (positron emission tomographycomputedy) showed a lesion suspected to be a locoregional recur-
rence at thin the gastrsurgery inpostoperatiresection hpancreatectOn histopain both therecurrence tion to sev(paclitaxel platin 25 m(MayJune rently 34 morder to deand to assescombinatio
3. Discussi
EGGCTs of testiculatesticular pmay be a brosis andineffective ity for CD 30 stain (400). (C) Positivity for PLAP stain (400). (D)
e site of the left adrenalectomy, and metastatic massic fundus (Fig. 6). The patient underwent desperation
April 2012. Previous interventions made disecretion ofve and tumour changes impossible and multivisceralad to be performed (en bloc gastrectomy with distalomy, left nephrectomy and splenic exure resection).thological analysis, metastatic embryonal carcinoma
gastric and colonic wall was found. No locoregionalwas conrmed, but the metastases had close rela-ere postoperative changes. Two cycles of 3rd-lineTIP250 mg/qm day 1, ifosfamid 1500 mg/qm day 25, cis-g/qm day 25) salvage chemotherapy were delivered2012). The patient has had regular follow-up, is cur-onths disease-free, and being carefully monitored intect relapse, development of secondary malignanciess cardiovascular events, whose frequency is higher aftern chemotherapy for germ cell tumours.
on
can be difcult to distinguish from metastatic tumoursr origin. Thorough testes investigation to rule outrimary is mandatory because the unrecognised tumoursource of relapse. In regressed tumours, moreover,
inadequate blood supply may render chemotherapy[2,10]. Although routine open testes biopsy is currently
-
CASE REPORT OPEN ACCESS38 M. Straka et al. / International Journal of Surgery Case Reports 10 (2015) 3540
Fig. 5. The sec(A) Metastatic(B) Suspected (C) CT reconst
not recommand proved
Seconda45% of patiand currenual retrope[11]. Resecthalf of theand teratomquacy of inconsidered vival in bocell tumourRPLND is tIn our casetions showRPLND, alththe patient resection orst diseasthe secondhistopatholond disease progression pattern at CT scanning (2012). lesion of gastric fundus.locoregional recurrence at the site of left adrenalectomy (colonic wall metastasis on naruction of disease extent in sagittal plane.
ended [5], in our case, bilateral biopsy was performed negative.ry surgery after 1st-line chemotherapy is performed inents with nonseminomatous retroperitoneal EGGCTstly is recommended for any postchemotherapy resid-ritoneal mass 1 cm in nonseminomatous tumoursed residuum consists of necrotic tissue in more than
patients, nondifferentiated tumour is found in 25%a like in our case in another 16% [5,12]. The ade-
itial retroperitoneal lymph node dissection (RPLND) isto be an independent predictor of disease-free sur-th low-stage and advanced nonseminomatous germs. The true incidence of retroperitoneal relapse afterhought to be underestimated and occurs late [13]., neither of the two subsequent surgical interven-
ed disease relapse inside the operating eld of initialough this could not be ruled out preoperatively andin the end underwent multivisceral resection to assuref all retroperitoneal disease. Histopathologically, thee relapse was localised within the left adrenal and
relapse in the gastric and in colonic wall. Only nalogical examination could dene the tumour origin pre-
cisely and dsurgeries.
In the rerecurrence prolonged sidered tumof them, thpostrelapsemalignant gnonseminoorigin. EGGprognosis [
In our pafree intervaadrenal pluby early sesurgery ansmall propdurable remunderwentlowed by 3G-CSF propl histopathology).
istinguish it from postoperative changes after previous
trospective analysis of Oldenburg et al. [14], late diseaseafter chemotherapy and radical RPLND does not excludesurvival. Twenty-two out of the 25 patients were con-our-free after treatment of the rst relapse. In sevene second relapse occurred, and the reported 10-year
survival was 68% [14]. In this analysis, however, allerm cells tumours were included (seminomatous andmatous) and only 4 cases were of primary extragonadalCTs relapsing after initial chemotherapy have a poor5].tient, tumour recurrence occurred after a long disease-l of 3.5 years. Extirpation of recurrence within the lefts 4 cycles of 2nd-line VeIP chemotherapy were followedcond tumour progression (9 months after the secondd 6 months after completion of chemotherapy). As aortion of patients with relapsed disease may achieveission with surgical resection alone [15,16], the patient
multivisceral resection as the rst therapeutic step, fol-rd-line adjuvant chemotherapy (2 cycles of TIP withhylaxis).
-
CASE REPORT OPEN ACCESSM. Straka et al. / International Journal of Surgery Case Reports 10 (2015) 3540 39
Fig. 6. The sec(A) Suspected (B) Metastatic(C) PET/CT rec
4. Conclus
While schemotheramass, repeaDesperatiobe an optionside-effectsa second orto ensure opatient with
Conict of
Martin S
Funding
Martin S
Ethical app
Not requond disease progression pattern at PET/CT scanning (2012).locoregional recurrence at the site of left adrenalectomy (colonic wall metastasis on na
lesion of gastric fundus.onstruction of disease extent in coronal plane.
ion
tandard 1st-line therapy in EGGCTs consists ofpy followed by surgery in patients with residualted tumour recurrences may pose a serious problem.n surgery with adjunctive salvage chemotherapy may
for otherwise t patients, who are able to tolerate the of repeated combined chemotherapy and surgery in
3rd-line treatment. Multidisciplinary decision-makingptimal timing of medical and surgical interventions in
recurrent tumour is mandatory.
interest statement
traka and other co-authors have no conict of interest.
traka and other co-authors have nothing to declare.
roval
ired.
Consent
Writtenpublicationof the writtof this journ
Author con
All autholowing: (1)(2) revisingnal approv
Guarantor
Martin S
References
[1] C. Rusnerpatterns tumours
[2] O. Preda,seminomtesticularl histopathology).
informed consent was conrmed from the patient for of this case report and accompanying images. A copyen consent is available for review by the Editor-in-Chiefal on request.
tributions
rs have made substantial contributions to all of the fol- acquisition of data, analysis and interpretation of data,
it critically for important intellectual content and (3)al of the version to be submitted.
traka.
, B. Trabert, A. Katalinic, J. Kieschke, K. Emrich, A. Stang, Incidenceand trends of malignant gonadal and extragonadal germ cellin Germany, 19982008, Cancer Epidemiol. 37 (4) (2013) 370373.
A. Nicolae, A. Loghin, A. Borda, F.F. Nogales, Retroperitoneala as a rst manifestation of a partially regressed (burnt-out)
germ cell tumor, Rom. J. Morphol. Ebryol. 52 (1) (2001) 193196.
-
CASE REPORT OPEN ACCESS40 M. Straka et al. / International Journal of Surgery Case Reports 10 (2015) 3540
[3] B.L. Balzer, T.M. Ulbright, Spontaneous regression of testicular germ celltumors. An analysis of 42 cases, Am. J. Surg. Pathol. 30 (2006)858865.
[4] S.B. Ricci, U. Crchiari, Spontaneous regression of malignant tumors:importance of the immune system and other factors (review), Oncol. Lett. 1(2010) 941945.
[5] H.J. Schmoll, Extragonadal germ cells tumors, Ann. Oncol. 13 (Suppl. 4) (2002)265272.
[6] International Germ Cell Cancer Collaborative Group, International Germ CellConsensus Classication, a prognostic factor-based staging system formetastatic germ cell cancers, J. Clin. Oncol. 15 (1997)594603.
[7] E.S. Leman, M.L. Gonzalgo, Prognostic features and markers for testicularcancer management, Indian J. Urol. 26 (2010) 7681.
[8] M.J. Garner, M.C. Turner, P. Ghadirian, D. Krewski, Epidemiology of testicularcancer: an overview, Int. J. Cancer 116 (2005) 331339.
[9] R.P.S. Trans-Atlantic Working Group, Management of primary retroperitonealsarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPSWorking Group, Ann. Surg. Oncol. 22 (1) (2015) 256263,http://dx.doi.org/10.1245/s10434-014-3965-2.
[10] J.C. Angulo, J. Gonzalez, N. Rodriguez, E. Hernandez, C. Nunez, J.M.Rodriguez-Barbero, A. Santana, J.I. Lopez, Clinicopathological study ofregressed testicular tumors (apparent extragonadal germ cell neoplasms), J.Urol. 182 (2009) 23032310.
[11] S.B. Riggs, E.F. Burgess, K.E. Gaston, C.A. Merwarth, D. Raghavan,Postchemotherapy surgery for germ cell tumors-what have we learned in 35years? Oncologist 19 (5) (2014) 498506,http://dx.doi.org/10.1634/theoncologist.2013-0379.
[12] C. Bokemeyer, C.R. Nichols, J.P. Droz, H.J. Schmoll, A. Horwich, A. Gerl, S.D.Fossa, J. Beyer, J. Pont, L. Kanz, L. Einhorn, J.T. Hartmann, Extragonadal germcell tumors of the mediastinum and retroperitoneum: results from aninternational analysis, J. Clin. Oncol. 20 (2002) 18641873.
[13] G.T. Gotto, B.S. Carver, P. Sogani, J. Sheinfeld, Surgery for retroperitonealrelapse in the setting of a prior retroperitoneal lymph node dissection forgerm cell tumor, Indian J. Urol. 26 (1) (2010) 102107,http://dx.doi.org/10.4103/0970-1591.60452.
[14] J. Oldenburg, G.C. Alfsen, H. Whre, S.D. Foss, Late recurrences of germ cellmalignancies: a population-based experience over three decades, Br. J. Cancer94 (6) (2006) 820827, http://dx.doi.org/10.1038/sj.bjc.6603014.
[15] T. Habuchi, T. Kamoto, I. Hara, K. Kawai, M. Nakao, N. Nonomura, T. Kobayashi,O. Ogawa, S. Kamidono, H. Akaza, A. Okuyama, T. Kato, T. Miki, Factors thatinuence the results of salvage surgery in patients with chemorefractorygerm cell carcinomas with elevated tumor markers, Cancer 98 (8) (2003)16351642.
[16] M.H. Voss, D.R. Feldman, G.J. Bosl, R.J. Motzer, A review of second-linechemotherapy and prognostic models for disseminated germ cell tumors,Hematol. Oncol. Clin. N. Am. 25 (3) (2011) 557576,http://dx.doi.org/10.1016/j.hoc.2011.03.007.
Open AccesThis article undepermits un any credited.s is published Open Access at sciencedirect.com. It is distributed restricted non commercial use, distribution, and reproduction in r the IJSCR Supplemental terms and conditions, whichmedium, provided the original authors and source are
Aggressive multimodal therapy may prolong disease-free survival in recurrent primary retroperitoneal embryonal carcinoma1 Introduction2 Presentation of the case3 Discussion4 ConclusionConflict of interest statementFundingEthical approvalConsentAuthor contributionsGuarantorReferences